SILO
Silo Pharma, Inc. (SILO) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
SILO’s environmental profile appears roughly in line with smaller biotech peers because R&D intensity is high, but the disclosed metrics do not show clear emissions leadership.
The company’s capital allocation is environmentally neutral versus peers, since heavy research spending supports innovation yet provides no evidence of superior resource efficiency or low-carbon operations.
No direct environmental controversies or compliance issues are provided, which avoids a peer-relative penalty, but the available data also do not indicate a differentiated sustainability advantage.
Because the business model is research-led rather than manufacturing-heavy, environmental exposure is likely less operationally intensive than industrial peers, though this is not enough for a strong score.
Social
SILO’s social positioning is mixed versus peers because high R&D spending can support patient-focused innovation, but the provided data do not evidence broader workforce or community strengths.
Stock-based compensation at 2.6% of revenue suggests moderate dilution pressure, which is manageable relative to peers but does not signal exceptional employee alignment.
No labor, safety, or product-responsibility controversies are disclosed in the provided inputs, limiting downside versus peers, yet the absence of evidence prevents a stronger assessment.
The company’s negative gross margin indicates a development-stage profile that can constrain social investment capacity relative to better-capitalized peers, without constituting a direct social weakness.
Governance
Governance appears somewhat better than many small-cap peers because debt-to-equity is zero, reducing creditor influence and financial constraint risk.
Net debt to EBITDA of 0.7x indicates conservative leverage, which supports governance flexibility versus more levered peers and lowers balance-sheet stress.
Stock-based compensation is present but not excessive, suggesting compensation discipline that is acceptable relative to peers rather than clearly superior.
The absence of disclosed board, audit, or controversy data limits confidence, so governance scores remain moderate despite the balance-sheet discipline shown in the metrics.
Overall Score
SILO’s ESG profile is broadly average versus peers, with modest governance discipline offset by limited evidence of differentiated environmental or social strengths.
Score Driver: Conservative Leverage And Manageable Compensation Support Governance, But The Available Data Do Not Show A Clear ESG Advantage Across The Other Dimensions.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Silo Pharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
